(Q46824175)

English

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase

scientific article published in December 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

0 references

tumor lysis syndrome

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Dieter Buchheidt

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

author name string

Margit Hummel

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Sebastian Reiter

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Jörg Bergmann

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Katja Adam

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Rüdiger Hehlmann

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

75

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

518-521

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Advances in the management of malignancy-associated hyperuricaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Tumour lysis syndrome: new therapeutic strategies and classification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Treatment of impending tumor lysis with single-dose rasburicase.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00550.X

21 January 2018

Identifiers

10.1111/J.1600-0609.2005.00550.X

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16313266

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46824175&oldid=2184252562"